Navigation Links
Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
Date:3/2/2011

EAST SETAUKET, N.Y., March 2, 2011 /PRNewswire/ -- Lixte Biotechnology Holdings (OTC: LIXT) announced today that the company has received a $244,479.25 grant under the Qualifying Therapeutic Discovery Project (QTDP).  This grant was awarded to further development and commercialization of Lixte's novel anti-cancer compound LB-100.  The QTDP program was included as part of the Patient Protection and Affordable Care Act of 2010 to encourage development of new therapies to prevent, diagnose, and treat acute and chronic diseases.  The selection process took into consideration the potential of projects to reduce long-term healthcare costs in the United States or significantly advance the goal of curing cancer over the next 30 years.  The selections were made jointly by the Department of Health and Human Services and the Treasury Department.  

"We are extremely pleased to have qualified for this grant," said Dr. John Kovach, founder and president of Lixte. "The funds will be used as part of our effort to complete pre-clinical studies and submit an IND to the FDA to bring our novel compound LB-100 to Phase I clinical trial. LB-100 represents a new type of anti-cancer drug, which we hope will improve treatments for several different types of human cancers for which more effective therapies are urgently needed."

About Lixte Biotechnology Holdings, Inc:Lixte Biotechnology Holdings, Inc. is a cancer therapeutics company. Founded as a biomarker-diagnostics company in 2005, Lixte primary focus is discovery of new chemotherapy drugs based on targeting molecular abnormalities of common human cancers critical to their survival.

Forward-Looking StatementsThis announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included on SEC Form 10-Q for the quarter ending September 30, 2010.Media contact:John S. Kovach, MDPresident & CEOLixte Biotechnology Holdings, Inc.248 Route 25A No. 2East Setauket, NY 11733Tel. 631-942-7959Fax 631-982-5050
'/>"/>

SOURCE Lixte Biotechnology Holdings
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lixte Biotechnology Holdings, Inc. Announces the Approval of a Collaboration with the National Cancer Institute for Clinical Evaluation of its Lead Anti-Cancer Compound, LB-100.
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
3. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
4. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
5. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
6. Pharma ChemOutsourcing Targets BioNJ, PA Bio, MassBio, BayBio, SoCalBio, and NY Biotechnology Association Member Companies for September 2011 Show in New Jersey
7. Reportlinker Adds Global Biotechnology Instrumentation Industry
8. NASDAQ Removes TLCR From Biotechnology Index Pending FTC Decision on Grifols Acquisition
9. Reportlinker Adds Global Agricultural Biotechnology Industry
10. Champions Biotechnology Awarded $1.46 million in Grants
11. Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... company, today announced that executive management will participate in ... held February 22-23, 2017. Adrian Adams , Chief ... at 1:35 p.m. local time on Wednesday, February 22, ... for the event may be accessed from the Investors ...
(Date:2/16/2017)... Scripts (NASDAQ: ESRX ) was recognized today by Fortune ... Health Care: Pharmacy and Other Services category. "Express Scripts ... Companies," said Tim Wentworth , CEO and President, Express Scripts. ... 26,000 employees to make medicine more affordable and accessible for the ... ...
(Date:2/16/2017)...  Prescription pain medications provided by "physicians in the ... long-term opioid use to take hold," according to a ... of The New England Journal of Medicine ... in acute pain than in almost any other medical ... of the American College of Emergency Physicians. "The challenge ...
Breaking Medicine Technology:
(Date:2/18/2017)... (PRWEB) , ... February 17, 2017 , ... Butler Mobility ... the Stannah Stairlift and other Butler products. Ken was impressed with the safety ... agreed to endorse the product on his show. This endorsement by Ken Matthews ...
(Date:2/18/2017)... ... February 18, 2017 , ... A ... information and contact points to easily connect elderly veterans of America's armed forces ... elder-care funding. It also conveys material on this year's increase in the Veterans ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy Network ... prescribing of controlled and non-controlled substances plus the ability to manage orders on ... United States now accept electronic prescriptions, according to the Office of the National ...
(Date:2/17/2017)... Church, VA (PRWEB) , ... February 17, 2017 ... ... Implementing the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? ...
(Date:2/17/2017)... ... 2017 , ... MAP Revenue Cycle Solutions (MAP RCS), a ... promoted to Chief Executive Officer. , The need for maximizing reimbursements while ... demands the transition from pay-for-service to pay-for-performance models. By delivering efficient and effective ...
Breaking Medicine News(10 mins):